MINI FUTURE ZERTIFIKAT LONG - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 18:36:00 20/06/2024 BST | ||
| 27.27 EUR | +1.30% |
|
| Current month | +5.82% | ||
| 1 month | +9.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 27.27 | +1.30% |
| 19/06/24 | 26.92 | -0.07% |
| 18/06/24 | 26.94 | -2.46% |
| 17/06/24 | 27.62 | -2.51% |
| 14/06/24 | 28.33 | +1.47% |
Real-time BOERSE MUENCHEN
Last update June 20, 2024 at 06:36 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | HSBC |
| WKN | TR0Y8Y |
| ISIN | DE000TR0Y8Y3 |
| Date issued | 16/10/2017 |
| Strike | 179.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 28.46 € |
|---|---|
| Lowest since issue | 1.51 € |
| Spread | 0.03 € |
| Spread % | 0.11% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
467.3
USD
Average target price
463.4
USD
Spread / Average Target
-0.83%
- Stock Market
- Certificates
- Certificat
